Morgan Stanley is a leading global financial services firm that provides a wide range of services in investment banking, securities, wealth management, and investment management. Catering to a diverse clientele that includes corporations, governments, and individuals, Morgan Stanley offers expert advisory and financing services, helping clients navigate complex financial markets and achieve their financial objectives. The firm is known for its strategic insights, innovative solutions, and commitment to delivering exceptional service, positioning itself as a trusted partner in the world of finance. Read More
American Airlines Group (NASDAQ:AAL) CEO Robert Isom said demand remains strong across the carrier’s network, cabins and geographies, while volatile fuel costs remain the principal constraint on profitability.
Speaking at a Morgan Stanley conference, Isom said American expects third-quarter revenue
Morgan Stanley Investment Management (MSIM) today announced the final close of the inaugural North Haven Growth & Innovation Fund (NHGIF or the Fund), oversubscribed with $1.3 billion in capital commitments. The Fund seeks to leverage the Integrated Firm, bringing together capabilities across Morgan Stanley's Investment Management, Institutional Securities and Wealth Management divisions, and drawing on the breadth of the Firm's relationships across the private growth ecosystem. Underscoring the Firm's alignment with investors, Morgan Stanley and its affiliates and employees collectively committed 24% of the Fund's capital.
GSK (NYSE:GSK) is pursuing a focused oncology expansion built around hematologic malignancies, gynecologic cancers, lung cancer, gastrointestinal cancers and prostate cancer, with a combination of internal research and business development, according to Hesham Abdullah, the company’s senior vice pre
Morgan Stanley Investment Management (MSIM) today announced an effort to convert eight municipal bond mutual funds into seven newly created exchange-traded funds (ETFs) and one existing ETF, representing nearly $10 billion in assets under management as of August 31, 2026. The Board of Trustees to the existing mutual funds approved the potential conversions, subject to approval by shareholders of each mutual fund and the satisfaction of other closing conditions. This effort reinforces MSIM’s commitment to expanding its ETF platform and highlights its focus on providing actively managed fixed income investment solutions in the ETF wrapper.
Morgan Stanley (NYSE:MS) Co-President Dan Simkowitz said the firm does not view 2026 as a peak-earnings year, citing growth opportunities in wealth management, a developing capital-markets recovery and continued financing demand tied to artificial intelligence.
Speaking at an investor conference, S
Honeywell International (NASDAQ:HON) Chairman and CEO Vimal Kapur said the company is seeing stronger-than-expected early-quarter momentum as it begins operating as a more focused automation business following the completed spins of its aerospace and advanced materials operations.
Speaking at a Mor
Amgen (NASDAQ:AMGN) outlined its growth priorities, late-stage pipeline progress and capital-allocation framework during a Morgan Stanley conference, as newly appointed Chief Financial Officer Thomas Dittrich emphasized execution, financial discipline and cash-on-cash returns.
Dittrich, who previou
Rivian Automotive (NASDAQ:RIVN) is entering what founder and CEO RJ Scaringe described as an “inflection point year,” as the electric-vehicle maker begins scaling its R2 midsize SUV and expands its software, autonomy and licensing initiatives.
Speaking at a Morgan Stanley event, Scaringe said the R
RTX (NYSE:RTX) Chairman, President and CEO Chris Calio said the aerospace and defense company remains positioned to benefit from sustained commercial aviation and defense demand, citing a $289 billion backlog that was up 22% from a year earlier.
Speaking at a Morgan Stanley aerospace and defense co
Medtronic (NYSE:MDT) Chief Financial Officer Thierry Piéton said the medical-device maker’s focus on acute procedures, expanding innovation pipeline and increased use of targeted acquisitions are supporting its recent growth momentum.
Speaking with Peter Harrison of Morgan Stanley Investment Bankin
General Motors (NYSE:GM) Chief Financial Officer Paul Jacobson said the automaker’s business is tracking consistently with its expectations for the third quarter, supported by resilient consumer demand, disciplined inventory management and production running near maximum levels across its system.
S
Gilead Sciences (NASDAQ:GILD) executives outlined plans to expand the company’s HIV prevention and treatment franchises while advancing oncology and inflammation programs, with Chairman and Chief Executive Officer Dan O’Day describing the company as being at an “inflection point in value.”
Speaking
AbbVie (NYSE:ABBV) executives outlined a pipeline and business-development strategy centered on immunology, neuroscience, oncology and obesity, while highlighting plans to expand beyond the company’s established SKYRIZI and RINVOQ franchises.
Speaking at a Morgan Stanley event, Chairman and Chief E
Check out the companies making headlines yesterday: Corning (NYSE:GLW): Glass and electronic component manufacturer Corning (NYSE:GLW) fell by 12.7% on Monda...
Sarepta Therapeutics (NASDAQ:SRPT) outlined plans to stabilize demand for its ELEVIDYS gene therapy while advancing RNA-based programs for facioscapulohumeral muscular dystrophy, or FSHD, and myotonic dystrophy type 1, or DM1, during a Morgan Stanley Global Healthcare Conference fireside chat.
Chie
Biogen (NASDAQ:BIIB) is reshaping its business around a broader mix of neuroscience, immunology, kidney disease and ophthalmology assets, President and CEO Chris Viehbacher said during a Morgan Stanley event. The company expects a series of late-stage clinical readouts to begin as soon as next quart
Viking Therapeutics (NASDAQ:VKTX) said its obesity drug candidate VK2735 has advanced into Phase 3 development following Phase 2 results that showed approximately 15% weight loss from baseline after 13 weeks at the highest tested dose.
Speaking at the Morgan Stanley Global Healthcare Conference, Pr
Regeneron Pharmaceuticals (NASDAQ:REGN) outlined growth opportunities for Dupixent, pipeline catalysts for cemdisiran and continued commercial momentum for EYLEA HD during the Morgan Stanley Global Healthcare Conference.
Marion McCourt, Regeneron’s EVP and head of commercial, said Dupixent’s growth
Teva Pharmaceutical Industries (NYSE:TEVA) CEO Richard Francis said the company has progressed from the initial phase of its “Pivot to Growth” plan into its next stage, citing momentum in branded medicines, innovation, generics and biosimilars, as well as improved financial flexibility.
Speaking at
CRISPR Therapeutics (NASDAQ:CRSP) CEO Sam Kulkarni outlined the company’s commercial and clinical priorities during a Morgan Stanley discussion, highlighting continued adoption of CASGEVY and expected data updates across several pipeline programs by the end of 2026.
Kulkarni said the company’s stra
Merck & Co., Inc. (NYSE:MRK) Chairman and CEO Rob Davis said the company’s “transformation is underway,” citing progress across product launches, clinical data readouts, business development and its Animal Health segment during a Morgan Stanley discussion.
Davis said recent pipeline readouts ha
